Director Lu Hongbo disclosed the purchase of 75,000 shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) common stock on March 31, 2026. The shares were acquired at $20.00 each, bringing the total value of the transaction to $1,500,000. Following the trade, Lu indirectly holds 422,968 shares.
The shares purchased were part of an underwritten public offering in which Zenas Biopharma sold common stock at $20.00 per share. The transaction took place against a recent backdrop in the market where the company's stock fell 13% over the prior week, while remaining up 131% over the trailing 12 months.
Concurrently, Zenas disclosed the pricing of two public financings. The company is offering $200 million in convertible senior notes and selling 5 million shares of common stock at $20.00 per share. The convertible notes carry a 2.50% interest rate, mature on April 1, 2032, and include a conversion price of approximately $26.50 per share.
On the clinical front, Zenas reported results from the MoonStone Phase 2 trial in Relapsing Multiple Sclerosis showing that its experimental therapy obexelimab produced a 95% reduction in brain lesions compared with placebo. The trial met its primary endpoint by demonstrating a reduction in new gadolinium-enhancing T1 lesions. The company also indicated an expected submission of a biologics license application for obexelimab in IgG4-related disease in the second quarter of 2026.
Market commentary noted shifting analyst views on Zenas. Guggenheim raised its price target to $55 and maintained a Buy rating, while Morgan Stanley increased its target to $21 and kept an Equalweight rating. Both firms cited developments in the company’s drug pipeline and the upcoming regulatory filing for obexelimab in IgG4-related disease.
Financial flexibility received attention as Zenas arranged a new debt facility with Pharmakon for up to $250 million, including an initial $75 million upfront, extending available resources into the next year. Despite these financing steps and clinical progress, InvestingPro analysis indicated the stock appears overvalued relative to its Fair Value, with shares trading at $19.55.
Lu’s purchase, the public offerings, the convertible note terms, the clinical data, analyst target changes, and the Pharmakon facility together outline recent material developments for Zenas BioPharma and provide a snapshot of the company’s capital and clinical position as of late March 2026.